Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Current Assets (2016 - 2025)

Cartesian Therapeutics (RNAC) has disclosed Current Assets for 11 consecutive years, with $129.3 million as the latest value for Q4 2025.

  • Quarterly Current Assets fell 40.32% to $129.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $129.3 million through Dec 2025, down 40.32% year-over-year, with the annual reading at $129.3 million for FY2025, 40.32% down from the prior year.
  • Current Assets for Q4 2025 was $129.3 million at Cartesian Therapeutics, down from $147.3 million in the prior quarter.
  • The five-year high for Current Assets was $229.1 million in Q3 2024, with the low at $89.9 million in Q3 2023.
  • Average Current Assets over 5 years is $149.2 million, with a median of $147.7 million recorded in 2022.
  • The sharpest move saw Current Assets soared 173.23% in 2021, then tumbled 43.72% in 2023.
  • Over 5 years, Current Assets stood at $144.4 million in 2021, then grew by 2.56% to $148.1 million in 2022, then tumbled by 38.75% to $90.7 million in 2023, then soared by 138.76% to $216.6 million in 2024, then tumbled by 40.32% to $129.3 million in 2025.
  • According to Business Quant data, Current Assets over the past three periods came in at $129.3 million, $147.3 million, and $163.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.